Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole- resistant oral candidiasis in HIV-1 infection

Infectious Diseases in Clinical Practice

Volumn 6, Issue 4, 1997, Pages 278-279

  Swindells, S ^a   Kleinschmidt, D R ^a   Hayes, F A ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CD4 ANTIGEN; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS RNA;

ADJUVANT THERAPY; ARTICLE; CASE REPORT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; THRUSH; VIRUS REPLICATION;

EID: 0030916107     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199705000-00019     Document Type: Article

References (15)

1. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173:219-25.
2. Boken DJ, Swindells S, Rinaldi MG Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17.1018-21.
3. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Fluconazole resistant mucosal candidiasis in advanced HIV infection [abstract MoB112] In: Program and abstracts of the International Conference on AIDS, July 7-12, 1996; Vancouver (BC), Canada.
4. Schuit K Phagocytosis and intracellular killing of pathogenic yeast by human monocytes and neutrophils Infect Immunol 1979;24: 932-8
5. Bodey GP The potential role of granulocytemacrophage colony-stimulating factor in therapy of fungal infections: a commentary. Eur J Clin Microbiol Infect Dis 1994;13:363-6.
6. Bender BS, Bohnsack JF, Sourlis SH. Demonstration of defective C3 receptor mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome. J Clin Invest 1987;79:715-20.
7. Metcalf D. The granufocyte-macrophage colony-stimulating factors. Science 1985;229: 16-22.
8. Smith PD, Lamerson CL, Banks SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 1990;161:999-1005.
9. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF), IL-3, granulocyte-macrophage-CSF, and macrophage-CSF J Immunol 1989;143:671-7.
10. Mayer P, Schutze E, Lam C, et al. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis 1991; 163:584-90.
11. Lechner AJ, Lamprech KE, Potthoff LH, et al. Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 1994;266:1561-8.
12. Gadish M, Kletter Y, Flidel O, et al. Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk Res 1991;15:1175-82.
13. Verhoef C, Boogaerts M. In vivo administration of granulocyte-macrophage colony-stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes. Br J Haematol 1991,79:177-84.
14. Perno C, Yarchoan R, Cooney DM, et al. Replication of human immunodeficiency virus in monocytes Granulocyte-macrophage colony-stimulating factor potentiates viral production yet enhances the antiviral effect mediated by 3′-azido 2′2′-dieoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989;169:933-51.
15. Scadden DT, Pickus O, Hammer SM, et al. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1 AIDS Res Hum Retroviruses 1996;12.1151-9